Review-PHARMACOTHERAPY IN THE TREATMENT OF OBESITY - ABSTRACT
Authors: Floriana Elvira Ionic? 1, Simona Negre? 2, Oana Cristina ?eremet 2, Cornel Chiri?? 2
1 University of Medicine and Pharmacy, Faculty of Pharmacy, Craiova, Romania
2 “Carol Davila” University of Medicine and Pharmacy, Faculty of Pharmacy, Bucharest, Romania
Background and Aims: In the last three decades, obesity and its related co morbidities has quickly increased. Sometime, obesity was viewed as a serious health issue in developed countries alone, but now is recognized as a worldwide epidemic, and its associated costs are enormous. Obesity is related with various diseases, like hypertension, type 2 diabetes mellitus (T2DM), dyslipidemia, chronic cardiovascular diseases, respiratory conditions, alongside chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This review purpose is to provide data on the current anti-obesity drugs, also available and in the development. Material and Methods: We searched MEDLINE from 2006 to the present to collect information on the anti-obesity pharmacotherapy. Results and Conclusions: In the patients with obesity related comorbidities, there may be an adaptation of the anti-obesity pharmacotherapy to the patients’ needs, in respect to the improvements of the cardiometabolic parameters. Although their efficacy was proven, the anti-obesity pharmacotherapies have presented adverse events that require a careful monitoring during treatment. The main obstacle for approve new drugs seems to be the ratio between the risks and the benefits, because of a long-time background of perilous anti-obesity drugs.
Key words: anti-obesity pharmacotherapy, diethylpropion, lorcaserin, orlistat, phentermine/topiramate